Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH.

Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH.
复制标题

DOI:
10.1038/srep03822
复制
发表时间:
2014-01-22
期刊:
影响因子:
4.6
通讯作者:
Tomita S
Tomita S
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Saito M;Tsounapi P;Oikawa R;Shimizu S;Honda M;Sejima T;Kinoshita Y;Tomita S

文献摘要

参考文献

被引文献

相似文献

鉴于越来越多的证据表明良性前列腺增生与心血管疾病有关,我们研究了自发性高血压大鼠(SHR)前列腺血流与前列腺增生的关系。12周龄雄性SHRs用尼可地尔治疗6周。Wistar-Kyoto大鼠作为对照。尼可地尔治疗6周后,测量血压和前列腺血流量,并测量组织中丙二醛、HIF-1α、TGF-β1、bFGF、双氢睾酮和α-SMA的水平。SHRs患者血压、组织中丙二醛、HIF-1α、TGF-β1、bFGF、α-SMA水平显著升高,前列腺血流量显著减少。虽然尼可地尔治疗不能改变血压和α-SMA,但能显著改善丙二醛、HIF-1α、TGF-β1和bFGF升高的水平。各组间双氢睾酮的组织水平无显著差异。这些数据表明,前列腺增生的发展可能与前列腺缺氧有关,而尼可地尔通过其增加血流量的作用来预防前列腺缺氧。
In the light of increasing evidence that benign prostatic hyperplasia is associated with cardiovascular disease, we have investigated the relationship between prostatic blood flow and prostatic hyperplasia in the spontaneously-hypertensive-rat (SHR). Twelve-week-old male SHRs were treated with nicorandil for six weeks. Wistar-Kyoto rats were used as controls. Six weeks after nicorandil treatment, blood pressure and the prostatic blood flow were estimated, and tissue levels of malondialdehyde, HIF-1α, TGF-β1, bFGF, dihydrotestosterone, and α-SMA were measured. SHRs showed significant increases in blood pressure, tissue levels of malondialdehyde, HIF-1α, TGF-β1, bFGF, α-SMA and a significant decrease in the prostatic blood flow. Although treatment with nicorandil failed to alter the blood-pressure and α-SMA, it significantly ameliorated the increased levels of malondialdehyde, HIF-1α, TGF-β1, and bFGF. There were no significant differences in tissue levels of dihydrotestosterone among any groups. These data indicate that development of prostatic hyperplasia may be associated with prostatic hypoxia, which nicorandil prevents via its effect to increase the blood flow.
DOI: 10.1074/jbc.m901790200
发表时间: 2009-06-19
期刊: The Journal of biological chemistry
影响因子: --
作者:
Mole DR;Blancher C;Copley RR;Pollard PJ;Gleadle JM;Ragoussis J;Ratcliffe PJ
通讯作者: Ratcliffe PJ
DOI: 10.2165/00003495-200060040-00007
发表时间: 2000-10-01
期刊: DRUGS
影响因子: 11.5
作者:
Markham, A;Plosker, GL;Goa, KL
通讯作者: Goa, KL
DOI: 10.3109/08977199809002121
发表时间: 1998-01-01
期刊: GROWTH FACTORS
影响因子: 1.8
作者:
Royuela, M;De Miguel, MP;Paniagua, R
通讯作者: Paniagua, R
DOI: 10.1182/blood-2004-07-2958
发表时间: 2005-01-15
期刊: BLOOD
影响因子: 20.3
作者:
Manalo, DJ;Rowan, A;Semenza, GL
通讯作者: Semenza, GL
DOI: 10.1056/nejmcp1106637
发表时间: 2012-07-19
影响因子: 158.5
作者:
Sarma, Aruna V.;Wei, John T.
通讯作者: Wei, John T.